In tumors, while blood-TCR-matched CD4+ cells also showed high frequencies of CXCL13+ and Tregs, this is because they were also prevalent among total CD4+ cells, indicating their basal contribution to the immune tumor microenvironment. This evidence concerns the gene CD4 and neoplasm.